Search results
At Viatris Canada, we see healthcare not as it is, but as it should be. We act courageously and are uniquely positioned to be a source of stability in a world of evolving healthcare needs. Viatris Canada empowers people to live healthier at every stage of life.
Viatris in Canada. Viatris in Canada works to empower people worldwide to live healthier at every stage of life. Because of our unwavering belief that better access leads to better health, we leverage our best-in-class manufacturing and proven commercial capabilities to bring quality medicines to patients when and where they need them.
Our global portfolio, supported by our science, medical and manufacturing expertise, delivers global iconic and key brands, biosimilars, generics - including complex and branded generics - and over-the-counter products.
Viatris is a global pharmaceutical company that believes in healthcare not as it is, but as it should be. Learn about our story, explore our products and browse career opportunities.
Ready for a new opportunity? Find your next role at Viatris and continue to build your career.
Viatris produces high quality medicines across a broad range of therapeutic areas. Explore our brands, generics, biosimilars, over-the-counter products and API.
The program provides tips and tools to help you get your Viatris original brand medication as well as information about your medication and health! We’re committed to helping you be an original—by staying on the Viatris original brand medication you know and trust.
Feb 18, 2021 · TORONTO and PITTSBURGH, Feb. 18, 2021 /CNW/ -- Viatris Inc. announced today that Health Canada has approved Hulio ®i, and product is now available in Canada. Hulio ® is a biosimilar to...
May 19, 2022 · In addition to the therapeutic area of oncology, Viatris Canada launched Hulio (adalimumab) in February 2021 for chronic inflammatory conditions. The Viatris Advocate™ program is also now available for Abevmy.
Apr 15, 2024 · Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the launch in Canada of PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, the first generic bioequivalent...
